NBQX (also known as FG9202) is a novel, potent selective and competitive antagonist of aminomethylphosphonic acid receptor (AMPAR) with IC50 of 0.7 ± 0.1 μM. It has the potential to treat seizure. Brief NBQX administration during the 48 h postseizure in P10 Long-Evans rats suppresses transient mTOR pathway activation and attenuates spontaneous recurrent seizures, social preference deficits, and mossy fiber sprouting observed in vehicle-treated adult rats after early life seizures. These results suggest that acute AMPAR antagonist treatment during the latent period immediately following neonatal HS can modify seizure-induced activation of mTOR, reduce the frequency of later-life seizures, and protect against CA3 mossy fiber sprouting and autistic-like social deficits.

纯度：≥98%

CAS：479347-86-9